Exclusive Summary

• Olanzapine, a well-established antipsychotic, benefits from expired original patents and a mature generic market with stable demand.
• US FDA GMP certification and registration experience ensure high quality and market access, facilitating international commercialization.
• Comprehensive dosage strengths (2.5mg-20mg) and cost-effectiveness position the product as a competitive generic option.
• Listed on WHO Essential Medicines List and recommended as a first-line treatment in guidelines, guaranteeing strong clinical relevance and physician recognition.
• Distribution partnership offers rapid market penetration by leveraging existing overseas sales networks.